An interventional study of Smartphone-based intervention messages in Tobacco Cigarette Smoking, sponsored by Johns Hopkins Bloomberg School of Public Health. Recruiting at 1 site in United States. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by Johns Hopkins Bloomberg School of Public Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 371 studies in Cigarette Smoking with a site in United States — 68 open to participants now, 75 under way, 3 of them phase 3. Cigarette Smoking · United States.
Among the 371 studies in Cigarette Smoking with a site in United States, this one is the 121st largest by planned enrollment of the 340 interventional ones that give a count, is one of 26 that started in 2024, is one of 226 with no phase, reaches primary completion later than 11 of the 74 other live ones, and was the 294th registered.
477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.
Browse Cigarette Smoking studies →68 of the 371 studies in Cigarette Smoking with a site in United States are open now. Recruiting first, the newest first:
Roswell Park Cancer Institute · Sites in United States
Ages 18–30
Virginia Polytechnic Institute and State University · Sites in United States
Ages 21+
University of California, Irvine · Sites in United States
Ages 50–80
VA Office of Research and Development · Sites in United States
Ages 21+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 21–50
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 62 Cigarette Smoking studies recruiting now, 38 (61%) set no upper age limit and 18 (29%) stop at 75 or younger; 1 takes children under 18; 33 take healthy volunteers.
This study: 18 Years to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
371 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 56 · Phase 3 10 · Phase 4 22
First in 1997; this study’s year is marked. 26 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 96 across 407 interventional studies indexed under Cigarette Smoking.
Median enrollment 96 across the 340 interventional studies, 159 across the 30 observational. Of the 280 that completed or were terminated, 137 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 371 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins Bloomberg School of Public Health is the lead sponsor of 371 studies on the registry; 41 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Johns Hopkins Bloomberg School of Public Health has 2 studies filed under Cigarette Smoking — fewer than ten, so there is no comparison to draw.
34 of the studies in Cigarette Smoking with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04176172Phase 3Abramson Cancer Center at Penn MedicineOptimizing Tobacco Use Treatment for PLWHA | 2026-11-30 |
| NCT05008848Phase 3Alliance for Clinical Trials in OncologyReaching Rural Cancer Survivors Who Smoke Using Text-Based Program | 2027-04-23 |
| NCT06945120Dana-Farber Cancer InstituteACT Lung Health Intervention: Phase Two | 2026-11-30 |
| NCT05836103Johns Hopkins Bloomberg School of Public HealthTesting the Impact of Smartphone-based Messaging to Support Young Adult Smoking Cessation | 2026-11-30 |
| NCT05707871Wake Forest University Health SciencesCardiovascular Effects of Very Low Nicotine Content Cigarettes | 2026-12 |
Add all 34 to your calendar (.ics) → With an account.
Among the 371 studies in Cigarette Smoking with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical practice guidelines for smoking cessation emphasize cognitive behavioral therapy (CBT) to help patients develop coping strategies for urges. Mindfulness or Acceptance and Commitment Therapy (ACT) offer a different approach, which teaches smokers psychological flexibility through accepting negative experiences. While there is evidence for the efficacy of both CBT and Mindfulness/ACT smoking cessation interventions, it is unclear if these approaches are efficacious when implemented in real-time and with young adults. The overall goal of this proposal is to evaluate the efficacy of CBT and Mindfulness/ACT messages for young adults targeted at specific high-risk situations for smoking.
This research will address the following specific aims:
Aim 1: To test CBT and Mindfulness/ACT intervention message efficacy for reducing momentary smoking urges (N=80). To inform just-in-time interventions, it is crucial to test if CBT and Mindfulness/ACT based messages can reduce momentary smoking urges. The investigators will conduct a micro-randomized trial (repeated within-subject randomizations of messages) to accomplish this. In line with the investigators' existing protocol, participants first collect Ecological Momentary Assessment (EMA) data for 14 days, allowing the investigators to determine high-risk situations for smoking. In the following intervention phase, participants receive tailored messages triggered by geofencing of participants' high-risk locations for a total of 30 days. Tailoring is based on established predictors of smoking relapse (stress and presence of other smokers). The micro-randomized trial tests the efficacy of CBT versus Mindfulness/ACT versus control messages for reducing smoking urge 15 minutes post message delivery. Secondary outcomes include smoking or other tobacco use (including e-cigarettes), affect, and stress.
Aim 2: To test if exposure to urge reduction messages results in changes in smoking behavior over time compared to an EMA only control group (N=80). It is important to investigate if repeated messages in the micro-randomized trial impact smoking behavior over time, in contrast to just repeated assessment without messages. Thus, this study includes a conventionally randomized clinical-trial component. Parallel to the micro-randomized trial group, a control group completes EMA surveys only without intervention messages. This allows the investigators to test if messages reduce smoking behavior. The primary outcome is number of cigarettes per day at end of treatment, 3-, and 6-months follow-up. Secondary analyses explore biochemically verified 7-day point prevalence abstinence, switching to e-cigarettes, and other tobacco outcomes. Post-hoc dose-response analyses investigate the long-term efficacy of CBT or Mindfulness/ACT messages on smoking behavior.
Aim 3: Explore moderation effects of substance co-use (cannabis, alcohol, other drugs) and exposure to specific location (home, work, bars) on urge reduction message efficacy. A crucial research question to inform future mobile interventions is how well intervention messages work in different situational contexts and when people are co-using other substances. Among intervention group participants, the investigators will explore how urge reduction message efficacy may be moderated by substance co-use and exposure to specific settings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The micro-randomized trial will determine if CBT and Mindfulness/ACT messages are superior to control messages in reducing the primary outcome momentary smoking urges. Based on participants' training data collected in the initial 14 days of EMA monitoring, intervention messages will be delivered during time-periods and at high-risk locations for smoking. In the intervention phase, participants will be prompted to complete 3 geofence-triggered EMAs per day for a total of 30 days. Each EMA will be followed by an intervention message and the type of message (CBT, Mindfulness/ACT, control) will be randomly selected at each time point (within-subject randomization).
Behavioral: Smartphone-based intervention messages
A total of N=80 participants will be randomized into an EMA-only control group, parallel to the micro-randomized trial intervention group. This group will conduct 14-day EMA only training phase just like the micro-randomized trial group, but will not be switched over to the intervention phase after these initial 14 days. Instead, participants will continue the EMA-only data collection procedure for an additional 30-days (analogous to the 30-day intervention phase of the micro-randomized trial). During these 30 days, the EMA-only control group will continue to receive 3 randomly prompted EMA surveys per day and an additional 3 EMA surveys triggered by smoking reports.
Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
Change in smoking urge as assessed by a single item
The primary outcome will be change in participants' rating of smoking urge in EMA-post surveys, prompted 15 minutes after intervention message delivery, and controlling for the ratings in EMA-pre surveys. Urge will be assessed by a single item on a 5-point scale, ranging from 1 (very low) to 5 (very high).
Time frame: 15 minutes after message delivery
Change in cigarettes smoked per day in past week as assessed by a single item
The primary outcome will be change in self-reported number of cigarettes smoked per day in the past week from baseline to 45-day, 3-month, and 6-month follow-up.
Time frame: Baseline, 45-day, 3-month, and 6-month follow-up
Smoking since intervention message delivery as assessed by a single item
Smoking in the 15 minutes after message delivery will be assessed by a single item on a binary response scale (yes/no).
Time frame: 15 minutes after message deliery
Other tobacco product use since intervention message delivery as assessed by a single item
Other tobacco product use, including e-cigarette use, in the 15 minutes after message delivery will be assessed by a single item on a binary response scale (yes/no).
Time frame: 15 minutes after message delivery
Change in stress as assessed by a single item
Change in rating of stress in EMA-post surveys, prompted 15 minutes after intervention message delivery, and controlling for the ratings in EMA-pre surveys. Stress will be assessed by a single item on a 5-point scale, ranging from 1 (very low) to 5 (very high).
Time frame: 15 minutes after message delivery
Change in negative affect as assessed by a single item
Change in rating of negative affect in EMA-post surveys, prompted 15 minutes after intervention message delivery, and controlling for the ratings in EMA-pre surveys. Negative affect will be assessed by a single item on a 5-point scale, ranging from 1 (very low) to 5 (very high).
Time frame: 15 minutes after message delivery
Message helpfulness as assessed by a single item
Rating of message helpfulness in EMA-post surveys, prompted 15 minutes after intervention message delivery. This will be assessed by a single item on a 5-point scale, ranging from 1 (not at all helpful) to 5 (extremely helpful).
Time frame: 15 minutes after message delivery
Activity completion as assessed by a single item
Self-reported completion of intervention message recommendation in EMA-post surveys, prompted 15 minutes after intervention message delivery will be assessed by a single item on a binary response scale (yes/no).
Time frame: 15 minutes after message delivery
Self-reported 7-day point prevalence abstinence as assessed by a single item
Self-reported 7-day point prevalence abstinence (no smoking, not even a puff) will be assessed by a single item on a binary response scale (yes/no).
Time frame: 45-day follow-up
Self-reported 7-day point prevalence abstinence as assessed by a single item
Self-reported 7-day point prevalence abstinence (no smoking, not even a puff) will be assessed by a single item on a binary response scale (yes/no).
Time frame: 3-month follow-up
Self-reported 7-day point prevalence abstinence as assessed by a single item
Self-reported 7-day point prevalence abstinence (no smoking, not even a puff) will be assessed by a single item on a binary response scale (yes/no).
Time frame: 6-month follow-up
Saliva-cotinine confirmed 7-day point prevalence abstinence
Saliva-cotinine confirmed 7-day point prevalence abstinence. This will be assessed using saliva test strips and photo confirmation.
Time frame: 45-day follow-up
Saliva-cotinine confirmed 7-day point prevalence abstinence
Saliva-cotinine confirmed 7-day point prevalence abstinence. This will be assessed using saliva test strips and photo confirmation.
Time frame: 3-month follow-up
Saliva-cotinine confirmed 7-day point prevalence abstinence
Saliva-cotinine confirmed 7-day point prevalence abstinence. This will be assessed using saliva test strips and photo confirmation.
Time frame: 6-month follow-up
Change in cigarettes smoked as assessed by a single item
Change (reduction) in cigarettes smoked by at least 50% between baseline and each follow-up timepoint. Reduction will be calculated based on self-reported number of cigarettes/day in the past week.
Time frame: Baseline, 45-day, 3-month, and 6-month follow-up
Tobacco quit attempt as a assessed by a single item
A tobacco quit attempt since last assessment will be assessed by a single item on a binary response scale (yes/no).
Time frame: Baseline, 45-day, 3-month, and 6-month follow-up
Change in frequency and intensity of smoking urges as assessed by two items of the Mood and Physical Symptoms Scale (MPSS)
Change in frequency and intensity of smoking urges will be assessed by two craving items from the Assessed with the Mood and Physical Symptoms Scale (MPSS) - subscale MPSS(C). Both items will be assessed on a 6-point scale from 0 (not at all / no urges) to 5 (all the time / extremely strong). Both items will be combined into the MPSS(C) subscale for analysis.
Time frame: Baseline, 45-day, 3-month, and 6-month follow-up
Change in psychological flexibility as assessed by the CompACT-15
Change in psychological flexibility from baseline to 45-day, 3-month, and 6-month follow-up will be assessed by the CompACT-15. The CompACT-15 total score ranges from 0-90, with higher scores indicating greater psychological flexibility.
Time frame: Baseline, 45-day, 3-month, and 6-month follow-up
Change in smoking-specific experiential avoidance as assessed by the Avoidance and Inflexibility Scale (AIS)
Change in smoking-specific experiential avoidance from baseline to 45-day, 3-month, and 6-month follow-up will be assessed by the Avoidance and Inflexibility Scale (AIS). Items are scored on a scale of 1-5 and combined into a total score. A higher total score indicates a more avoidant and inflexible response to internal states associated with smoking.
Time frame: Baseline, 45-day, 3-month, and 6-month follow-up
Tobacco product switching as assessed by 5 questions
Switching to other tobacco products including e-cigarettes from baseline to 45-day, 3-month, and 6-month follow-up will be assessed using questions about past 7-day use of cigarettes, e-cigarettes, cigars / cigarillos / little cigars, smokeless tobacco, and hookah / waterpipe. Participants will be coded as having switched if they do not report cigarette smoking, but use of another tobacco product at a follow-up assessment.
Time frame: Baseline, 45-day, 3-month, and 6-month follow-up
Plan to share: Yes — Any individual requests for data will be honored on a case-by-case basis as deemed appropriate to the research protocol.
Supporting information: Study protocol, Analytic code
Started Oct 2024 (actual). Primary completion is estimated for Nov 2026, 25 months after the start.
Of 185 non-industry interventional studies with no phase under Cigarette Smoking, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's planned 25 months is above that.
Counting every sponsor, half of 192 studies reached it within 20 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johns Hopkins Bloomberg School of Public Health →